Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?
H Smith, E Arbe-Barnes, EA Shah… - Frontiers in …, 2024 - frontiersin.org
The five-year survival rates for pancreatic ductal adenocarcinoma (PDAC) have scarcely
improved over the last half-century. It is inherently resistant to FDA-approved …
improved over the last half-century. It is inherently resistant to FDA-approved …